New research from dario demonstrates ability to deliver improved health outcomes with integrated solution for members managing weight and blood glucose with or without glp-1 medications

Study presented at attd 2024 is the first of a planned series examining the impact of dario's integrated cardiometabolic solution as a means to address weight and diabetes with or without a glp-1 additional research presented demonstrated dario's ability to improve awareness of the importance of flu vaccines in member with type 2 diabetes new york , march 12, 2024 /prnewswire/ -- dariohealth corp. (nasdaq: drio) (the "company"), a leader in the global digital therapeutics (dtx) market, announced today two new clinical studies presented at the 17th international conference on advanced technologies and treatments for diabetes (attd) 2024, held march 6 – 9 in florence, italy. examining evolving standards for metabolic health: improving outcomes with or without medication the introduction of glp-1s as an effective tool for both weight loss and diabetes management is evolving the standards of care for metabolic health conditions.
DRIO Ratings Summary
DRIO Quant Ranking